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was similar. There was no effect on HD session on VAP-1 
concentration. Diabetic patients had higher serum VAP-1 
than non-diabetic.
Conclusions HDF is associated with lower VAP-1 lev-
els indicating less pronounced endothelial cell injury than 
hemodialysis. Type of heparin seems to have no effect 
on VAP-1 levels in hemodialyzed patients. However, the 
cross-sectional but not prospective design is a limitation of 
this study.
Keywords Hemodialysis · Hemodiafiltration · VAP-1 · 
Anticoagulation · UFH · LMWH
Introduction
Vascular adhesion protein-1 (VAP-1) is a copper-con-
taining semi-carbazide-sensitive amine oxidase (SSAO) 
secreted by vascular smooth muscle cells, adipocytes and 
endothelial cells with functional monoamine oxidase activ-
ity [1]. On the other hand, endothelial VAP-1 can act as an 
adhesion molecule [2] and is involved in leukocyte rolling, 
adhesion and transmigration, which are central steps dur-
ing leukocyte extravasation to sites of inflammation, such 
as atherosclerotic lesions [3]. Hemodiafiltration (HDF) is a 
combination of convective and diffusive processes for sol-
ute removal, i.e., a combination of intermittent hemofiltra-
tion with simultaneous hemodialysis. Convection favors 
the elimination of higher molecular weight substances, 
whereas low molecular weight substances are removed 
from the blood by diffusion. Klingel et al. [4] have reported 
that HDF in comparison with high-flux HD was associ-
ated with increased procoagulant activity in the extracor-
poreal circuit. We have shown previously that patients on 
HD showed evidence of a higher degree of endothelial 
Abstract 
Purpose Traditional anticoagulants used in intermittent 
hemodialysis (HD) are unfractionated heparin (UFH) and 
increasingly low molecular weight heparins (LMWHs). 
Repeated and prolonged exposure to UFH and/or LMWHs 
may further disturb hemostasis in uremic patients. Vas-
cular adhesion protein-1 (VAP-1) is secreted by vascular 
smooth muscle cells, adipocytes and endothelial cells with 
functional monoamine oxidase activity and is elevated in 
atherosclerosis, diabetes mellitus and obesity. The aim of 
this study was to assess the effects of UFH and LMWHs on 
VAP-1 concentration in HD patients. The effects on single 
HD session on VAP-1 were also evaluated as well as VAP-1 
levels in regard to type of renal replacement therapy.
Methods We studied 82 hemodialyzed patients (mean 
age 63 years, dialysis vintage 59 months) and 17 patients 
treated by means of hemodiafiltration (HDF) (mean age 
59 years, HD vintage 84 months, HDF 7 months). Patients 
were anticoagulated with enoxaparin (n = 46), dalteparin 
(n = 10), nadroparin (n = 6) or UFH (n = 20) during their 
HD sessions. VAP-1 was assessed using kits from BioVen-
dor, Modrice, Czech Republic.
Results Patients on HDF had significantly lower VAP-1 
when compared with HD patients. We found that VAP-1 
concentration in patients dialyzed by using LMWH or UFH 
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dysfunction than HDF subjects [5]. It appears that HD 
procedures induce stimulation and damage of endothelial 
cells and that long-term, recurrent HD treatment may pre-
dispose to vascular disorders [6]. Up to authors’ knowl-
edge, there are no data on the VAP-1 levels in HDF, and 
in addition there are no reports on effects of heparin on 
VAP-1 in patients maintained on chronic HD. Taking all 
these data into consideration, the aim of the study was to 
assess VAP-1 levels in regard to type of renal replacement 
therapy, as well as the effects on HD session on VAP-1 lev-
els in regard to three types of low molecular weight heparin 
(LMWH) and unfractionated heparin (UFH).
Materials and methods
The study was performed on 82 patients with end-stage 
renal failure treated by means of chronic HD and 17 by 
HDF. Inclusion criteria were: a stable clinical state, no 
thrombosis or inflammation, (C-reactive protein within nor-
mal range, below 6 mg/dL according to the central labora-
tory cutoff), absence of acute cardiovascular complications 
(including uncontrolled hypertension, recent myocardial 
infarction within 30 days, etc.), no oral contraception in 
women of child-bearing age, stable and no more than twice 
of the normal GOT and GPT activities. None of the patients 
investigated had received blood transfusions for at least 
1.5 months, and no drugs known to affect hemostasis were 
administered for at least 2 weeks prior to the study. Patients 
were selected from the group of HD subjects who had 
been receiving enoxaparin (n = 46), dalteparin (n = 10), 
nadroparin (n = 6) or UFH (n = 20) as an anticoagulant 
during their HD sessions. At the beginning of HD, enoxa-
parin (Clexane, Sanofi-Aventis, Paris, France), dalteparin 
(Fragmin, Pfizer Europe, Sandwich, Kent, UK) or nadro-
parin (Fraxiparie, GlaxoSmithKline, Brentford, Middlesex, 
UK) were administered as a single bolus of 40 mg (20–
80 mg), 5000 IU (2500–7500 IU) or 3800 IU anti-Xa IU 
(2850–5700 anti-Xa IU), respectively, into the predialyzer 
arterial line. The effective dose of enoxaparin, dalteparin or 
nadroparin was 50 ± 15 mg (1 mg = 100 IU of anti-fac-
tor Xa activity), 5000 ± 1291 IU or 4050 ± 1090 anti-Xa 
IU, respectively. The dose was established on the basis of 
clinical guidelines: no visible fibrin clots in the arterial and 
venous bubble traps during HD, no clotted filters after HD 
and no bleeding from the fistula puncture sites after com-
pression [7, 8] and was similar to previously reported [7–
9]. UFH (Heparinum, Polfa, Warsaw, Poland) was admin-
istered as a loading dose of 2500 IU (1500–4000 IU) into 
the arterial line prior to the onset of HD session, followed 
by a continuous infusion of 3500 (2500–4500) IU via a 
syringe pump during HD. The infusion was stopped 30 min 
before the scheduled end of HD session. The effective dose 
of UFH was established individually by titration during the 
first three HD sessions. It was based on the whole-blood 
activated partial thromboplastin time, which was about 
twofold prolonged at both 30 and 120 min after the onset 
of HD relative to the baseline. For HDF population only 
enoxaparin was used.
In all dialyzed patients, blood was drawn in the morn-
ing between 8.00 a.m. and 9.00 a.m. before administra-
tion of anticoagulant and after HD/HDF from the arterial 
line of HD system immediately before discontinuation of 
the extracorporeal circulation (only for urea concentra-
tion necessary for Kt/V determination). Blood was taken 
without stasis. Venous blood samples were collected into 
3.8% sodium citrate in 9:1 volume ratio. Samples were ali-
quoted and stored at −80 °C before assay. All subjects gave 
informed consent, and the protocol was approved by the 
Medical University Ethics Committee. VAP-1 was assessed 
using kits from BioVendor, Modrice, Czech Republic. Data 
given were analyzed using Statistica 10.0 computer soft-
ware (Tulsa, OK, USA). Normality of variable distribu-
tion was tested using Shapiro–Wilk W test. Measurements 
normally distributed are reported as mean ± SD. ANOVA 
or Mann–Whitney rank-sum U test or Student’s t test was 
used in statistical analysis to compare differences between 
groups with p < 0.05 considered statistically significant, 
when appropriate. Multiple regression analysis was used 
to determine independent factors affecting dependent 
variable. Factors showing linear correlation with VAP-1 
(p < 0.1) were included in the analysis. Adjustments for the 
dialysis modality were performed.
Results
Basic clinical and biochemical characteristics of the stud-
ied patients are given in Table 1. Patients on HDF had sig-
nificantly lower VAP-1 when compared with HD patients 
(Table 1). Patients’ hypertension (n = 82) had higher 
VAP-1 levels when compared with patients with normo-
tension (335.30 ± 104.04 vs. 256.94 ± 129.12 ng/mL, 
p < 0.05). Patients with coronary artery disease (n = 67) 
had higher VAP-1 than patients without coronary artery 
disease (310.57 ± 172.16 vs. 239.34 ± 129.08 ng/mL, 
p < 0.05). Patients with residual renal function (n = 36) had 
lower VAP-1 than patients without residual renal function 
(243.03 ± 113.45 vs. 319.28 ± 139.73 ng/mL, p < 0.05). 
Diabetic patients (n = 24) had higher VAP-1 than non-
diabetic (361.54 ± 123.86 vs. 291.43 ± 118.76 ng/mL, 
p < 0.05). The data were the same for HD and HDF group; 
therefore, they are presented as a whole group.
In univariate analysis, VAP-1 correlated with pres-
ence of diabetes (r = 0.29, p < 0.05), presence of hyper-
tension (r = 0.23, p < 0.05), ejection fraction (r = −0.43, 
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p < 0.01), cholesterol (r = −0.23, p < 0.05), serum iron 
(r = −0.23, p < 0.05), ferritin (r = −0.28, p < 0.05). In 
multiple regression analysis, VAP-1 was predicted in 44% 
by serum ejection fraction (beta value 0.36, p = 0.014), and 
ferritin (beta value 0.25, p = 0.039) F = 4.33, SE = 137.89 
and p < 0.001.
We found that VAP-1 concentration in patients dialyzed 
by using enoxaparin, fraxiparine, dalteparin or UFH was 
similar (Fig. 1).
Discussion
In our study we compared two dialysis modalities: HD 
and HDF. Chronic HDF is a relatively simple option of 
renal replacement therapy that may offer significant ben-
efits for many patients who have end-stage renal disease 
and deserve closer consideration for these patients. As 
HDF favors the elimination of higher molecular weight 
substances, we assessed VAP-1 in HDF patients. In this 
Table 1  Clinical and 
biochemical characteristics of 
studied groups
* p < 0.05, ** p < 0.01 HD versus HDF
HD (n = 82) HDF (n = 17)
Age (years) 63 ± 17 59 ± 14
Time of renal replacement therapy (months) 59 ± 35 HD 84 ± 50
HDF 7 ± 2
Residual renal function (mL/24 h) 400 (0;1500) 200 (0;800)
KT/V 1.18 ± 0.24 1.28 ± 0.16*
Iron (μg/dL) 68.92 ± 24.65 115.64 ± 47.43**
TSAT (%) 24.57 ± 8.75 35.67 ± 9.43*
Ferritin (ng/mL) 415 (179;697) 527 (274;811)
Hemoglobin (g/dL) 11.63 ± 1.42 11.32 ± 1.35
EPO dose (U/week) 4111 ± 2778 3782 ± 2643
Total cholesterol (mg/dL) 178.65 ± 49.65 151.65 ± 50.74*
Total protein (g/dL) 6.52 ± 0.71 6.59 ± 0.55
Albumin (g/dL) 3.91 ± 0.41 3.84 ± 0.48
Total calcium (mmol/L) 2.31 ± 0.29 2.23 ± 0.34
Phosphates (mg/dL) 6.04 ± 2.39 5.79 ± 2.89
Ejection fraction (EF) (%) 59.18 ± 10.48 57. 55 ± 8.19
VAP-1 (ng/mL) 326.11 ± 119.60 240.66 ± 109.22*
Diabetes (%) 24 24
Hypertension (%) 83 82
Coronary artery disease (%) 67 71
Fig. 1  Effects of single dialysis 
session and different heparins 
on VAP-1 in hemodialyzed 
patients
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paper we showed for the first time that VAP-1 levels were 
significantly lower in HDF when compared to HD, simi-
larly to our previous study on renalase [10]. Moreover, we 
could show the effect of residual renal function on VAP-1 
levels in larger group of patients than we presented previ-
ously [11]. Lin et al. [12] reported that VAP-1 levels were 
positively associated with the urinary albumin-to-creatinine 
ratio and inversely correlated with estimated GFR, suggest-
ing that serum VAP-1 might be excreted by the kidneys. 
These data support our findings. Moreover, in kidney trans-
plant recipients VAP-1 correlated with kidney function and 
endothelial damage as well [13]. We observed that patients 
with coronary artery disease had higher VAP-1 levels than 
patients without coronary artery disease. We did not see the 
effect in the smaller group [11]. Serum VAP-1 can indepen-
dently predict 10-year all-cause mortality, cardiovascular 
mortality, in subjects with type 2 diabetes [14]. In addition, 
in heart transplant recipients VAP-1 was related to heart 
function and kidney function [15], which corroborates with 
presented data. In prospective cohort study (the FINRISK 
2002) on 2775 participants (mean age, 60 years) followed 
up of 9 years, 265 participants underwent a major adverse 
cardiovascular event (MACE), and these participants had 
higher levels of VAP-1 than those without MACE (868 and 
824 ng/mL, respectively, p < 0.001) [16]. Aalto et al. [16] 
concluded that VAP-1 independently predicted incident 
MACE (p = 0.0046) and MACE mortality (p = 0.026) in 
general population over 50 years of age. They also sug-
gested that VAP-1 may be a potential new biomarker for 
cardiovascular diseases. Ferritin was one of the predictors 
of VAP-1 in our population. Being the acute-phase reactant, 
not only the iron storage protein [17], ferritin, paralleled 
VAP-1 levels in diabetic dialyzed patients [18].
As endothelial dysfunction in common in chronic kid-
ney disease [19] and endothelial VAP-1 can participate in 
inflammation by binding granulocytes, lymphocytes and 
monocytes, with the aid of SSAO activity [1, 2], VAP-1 
might be considered as a novel biomarker for cardiovas-
cular diseases in kidney patients, in particular those with 
diabetes.
The new and interesting points of the study are the pos-
sible effects of the type of dialysis and the type of hepa-
rin on VAP-1 levels. Up to the authors’ knowledge, there 
are no data comparing dalteparin, nadroparin and enoxa-
parin with UFH in regard to VAP-1. We reported for the 
first time the effects of different heparins on VAP-1 in HD 
patients, but we found that VAP-1 seemed to be unaffected 
by dialysis session. VAP-1 is a dual-function protein and 
can participate in the development and progress of athero-
sclerosis [20]; however, linking the degree of endothelial 
dysfunction with use of anticoagulants with their long-term 
consequences needs prospective studies. As in the recent 
study, Lavainne et al. [21] indicated that heparin-based 
HD induced a major release of sFlt1, a potent inhibitor of 
vascular endothelial growth factor, which may exacerbate 
the anti-angiogenic state and thus endothelial dysfunction, 
commonly found in dialysis patients. In our previous study, 
we reported that LMWH influences thrombin-activatable 
fibrinolysis inhibitor (TAFI) and other hemostatic param-
eters in hemodialyzed patients to a lesser degree than UFH 
[22]. Long-term use of anticoagulants in HD patients may 
thus influence endothelial function.
Our study has several limitations due to its cross-sec-
tional design, which makes it difficult to determine the 
causality between serum VAP-1 and HDF and type of anti-
coagulation. The small sample size and enrollment in such 
an ethnically homogeneous Caucasian population limit the 
results to be generalized, but the study was performed on 
HD and HDF population which could be an advantage. 
The majority of studies in renal replacement therapy are 
designed for HD patients, and sometimes it is difficult to 
extrapolate the data into other modality of dialysis. The 
small sample in regard to HDF population is due to the fact 
that this modality is not reimbursed, and thus, the differ-
ence in costs between HD and HDF is covered by dialy-
sis unit which limits the possibility to offer HDF to more 
patients. We should bear in mind that choosing the best 
dialysis modality and type of anticoagulation depends not 
only on the clinical status but also on price and healthcare 
policy.
In conclusion, HDF is associated with lower VAP-1 lev-
els indicating less pronounced endothelial cell injury favor-
ing thus type of treatment. Type of heparin seems to have 
no effect on VAP-1 levels in HD patients. However, the 
cross-sectional but not prospective design is a limitation of 
this study.
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